Skip to main content

Table 4 Predicted birth incidence of disease by population

From: Predicting disease severity in metachromatic leukodystrophy using protein activity and a patient phenotype matrix

Population

Adult

Juvenile

Infantile/late-infantile

Overall

Unknown

Asymptomatic

Patient-based severity frequencies

 All

1 in 982,195 (1 in 1,217,194–1 in 809,415)

1 in 922,918 (1 in 1,161,876–1 in 750,959)

1 in 897,800 (1 in 1,171,025–1 in 710,374)

1 in 310,996 (1 in 378,659–1 in 260,026)

1 in 11,635 (1 in 10,688–1 in 12,660)

1 in 2.0 (1 in 2.0–1 in 2.0)

 African

1 in 14,176,960 (1 in 831,913,558–1 in 3,652,135)

1 in 4,702,212 (1 in 34,035,787–1 in 1,743,843)

1 in 6,238,516 (1 in 103,014,176–1 in 1,938,642)

1 in 2,254,805 (1 in 14,451,246–1 in 863,371)

1 in 1,500 (1 in 1,207–1 in 1,885)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Ashkenazi Jew

1 in 16,037,127 (1 in 5,420,710,450–1 in 3,467,993)

1 in Inf (1 in NA–1 in NA)

1 in 96,905,713 (1 in 103,489,540,292,125,616–1 in 11,904,593)

1 in 13,759,963 (1 in 8,104,690,917–1 in 2,848,333)

1 in 98,975 (1 in 52,193–1 in 229,712)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Latino

1 in 7,251,699 (1 in 34,320,883–1 in 3,034,293)

1 in 6,030,699 (1 in 26,581,588–1 in 2,582,041)

1 in 2,102,282 (1 in 5,968,435–1 in 1,061,892)

1 in 1,283,054 (1 in 3,111,363–1 in 696,030)

1 in 27,551 (1 in 21,067–1 in 37,271)

1 in 2.0 (1 in 2.0–1 in 2.0)

 East Asian

1 in 8,241,012 (1 in 247,204,015–1 in 2,322,923)

1 in 4,499,667 (1 in 50,973,627–1 in 1,504,673)

1 in 1,193,952 (1 in 4,829,714–1 in 526,209)

1 in 846,642 (1 in 2,912,020–1 in 395,744)

1 in 3,775 (1 in 3,023–1 in 4,831)

1 in 4.0 (1 in 4.0–1 in 4.0)

 Finnish

1 in 632,277 (1 in 1,473,092–1 in 349,708)

1 in 1,348,377 (1 in 4,014,767–1 in 667,509)

1 in 9,597,657 (1 in 112,527,413–1 in 3,186,559)

1 in 411,962 (1 in 934,766–1 in 230,856)

1 in 146,251 (1 in 89,716–1 in 274,619)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Non-Finnish European

1 in 383,549 (1 in 496,456–1 in 305,296)

1 in 385,798 (1 in 511,958–1 in 301,227)

1 in 336,590 (1 in 461,907–1 in 256,240)

1 in 122,395 (1 in 154,982–1 in 99,129)

1 in 32,069 (1 in 27,364–1 in 37,914)

1 in 2.0 (1 in 2.0–1 in 2.0)

 South Asian

1 in 23,128,011 (1 in 230,477,824–1 in 7,950,208)

1 in 24,809,733 (1 in 344,874,636–1 in 7,961,844)

1 in 11,430,966 (1 in 85,649,278–1 in 4,202,324)

1 in 5,847,063 (1 in 27,595,032–1 in 2,448,746)

1 in 2,856 (1 in 2,434–1 in 3,377)

1 in 3.0 (1 in 3.0–1 in 3.0)

 Other

1 in 321,219 (1 in 1,299,900–1 in 141,551)

1 in 350,719 (1 in 1,793,905–1 in 143,259)

1 in 441,214 (1 in 4,014,613–1 in 154,808)

1 in 121,493 (1 in 461,869–1 in 54,729)

1 in 7,989 (1 in 5,009–1 in 13,802)

1 in 2.0 (1 in 2.0–1 in 2.0)

Activity-based severity frequencies (95% CI)

 All

1 in 573,791 (1 in 710,318–1 in 473,265)

1 in 1,917,472 (1 in 2,816,519-1 in 1,389,872)

1 in 319,444 (1 in 391,416–1 in 265,699)

1 in 185,365 (1 in 220,577–1 in 157,985)

1 in 798,906 (1 in 605,837–1 in 1,128,508)

1 in 2.0 (1 in 2.0–1 in 2.0)

 African

1 in 3,681,593 (1 in 39,388,957–1 in 1,246,120)

1 in 7,527,795 (1 in 453,677,291–1 in 1,932,964)

1 in 970,308 (1 in 3,884,229–1 in 429,195)

1 in 696,833 (1 in 2,382,388–1 in 326,467)

1 in 2,147,028 (1 in 671,520–1 in Inf)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Ashkenazi Jew

1 in Inf (1 in NA-1 in NA)

1 in Inf (1 in NA-1 in NA)

1 in Inf (1 in NA-1 in NA)

1 in Inf (1 in NA-1 in NA)

1 in 10,664,166 (1 in 2,142,447–1 in Inf)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Latino

1 in 5,080,870 (1 in 21,100,323–1 in 2,219,182)

1 in 10,340,390 (1 in 101,625,721–1 in 3,565,435)

1 in 1,523,627 (1 in 3,909,659–1 in 804,944)

1 in 1,052,794 (1 in 2,425,110–1 in 585,563)

1 in 2,892,784 (1 in 1,302,936–1 in 16,137,288)

1 in 2.0 (1 in 2.0–1 in 2.0)

 East Asian

1 in 1,168,036 (1 in 3,548,349–1 in 573,449)

1 in 1,538,467 (1 in 5,990,990–1 in 687,123)

1 in 830,752 (1 in 2,851,688–1 in 388,610)

1 in 369,022 (1 in 930,942–1 in 196,496)

1 in 206,362 (1 in 116,392–1 in 453,224)

1 in 4.0 (1 in 4.0–1 in 4.0)

 Finnish

1 in 904,289 (1 in 2,118,248–1 in 498,834)

1 in 1,139,390 (1 in 3,354,396–1 in 566,721)

1 in 697,186 (1 in 1,829,319–1 in 364,606)

1 in 292,582 (1 in 609,206–1 in 171,392)

1 in 282,508 (1 in 154,302–1 in 675,835)

1 in 2.0 (1 in 2.0–1 in 2.0)

 Non-Finnish European

1 in 242,771 (1 in 314,762–1 in 192,988)

1 in 1,274,476 (1 in 2,322,899–1 in 804,303)

1 in 140,758 (1 in 181,201–1 in 112,521)

1 in 83,277 (1 in 103,413–1 in 68,514)

1 in 1,459,174 (1 in 865,972–1 in 3,501,638)

1 in 2.0 (1 in 2.0–1 in 2.0)

 South Asian

1 in 2,326,525 (1 in 7,553,334–1 in 1,112,061)

1 in 2,965,978 (1 in 12,177,600–1 in 1,300,518)

1 in 625,516 (1 in 1,343,427–1 in 360,494)

1 in 422,715 (1 in 830,376–1 in 255,587)

1 in 2,276,709 (1 in 993,988–1 in 12,672,316)

1 in 3.0 (1 in 3.0–1 in 3.0)

 Other

1 in 254,514 (1 in 1,258,278–1 in 105,052)

1 in Inf (1 in NA-1 in NA)

1 in 140,400 (1 in 602,201–1 in 60,658)

1 in 90,485 (1 in 311,412–1 in 42,285)

1 in 576,125 (1 in 150,023–1 in Inf)

1 in 2.0 (1 in 2.0–1 in 2.0)

  1. Burdens for each MLD subtype were predicted using allele frequencies from gnomAD and our phenotype matrix. Calculations were performed using patient-based severity, as defined by our variant-severity criteria, and repeated using activity-based severity determined by tandem mass spectrometry (MS/MS). 95% percent confidence intervals were calculated using the analytical method, except for the “Unknown” and “Asymptomatic” incidence rates, which rely on 95% confidence intervals calculated through numeric simulation